Literature DB >> 22291728

Osteoporosis, osteopenia, and atherosclerotic vascular disease.

Wilbert S Aronow1.   

Abstract

Older women with low bone mineral density (BMD) have a higher prevalence of atherosclerotic vascular disease (coronary artery disease, ischemic stroke, or peripheral arterial disease) than older women with normal BMD. Three coronary angiographic studies have shown that low BMD is associated with obstructive coronary artery disease. Low BMD has been shown to be associated with stress test-induced myocardial ischemia, reduced exercise capacity, and with aortic valve calcification. Women with osteoporosis have an increased risk for cardiovascular events. Treatment of osteoporosis or osteopenia should include therapeutic measures to prevent cardiovascular events.

Entities:  

Keywords:  atherosclerotic vascular disease; bone mineral density; coronary artery disease; myocardial ischemia; osteopenia; osteoporosis

Year:  2011        PMID: 22291728      PMCID: PMC3258682          DOI: 10.5114/aoms.2011.20599

Source DB:  PubMed          Journal:  Arch Med Sci        ISSN: 1734-1922            Impact factor:   3.318


Introduction

According to the criteria of the World Health Organization, osteoporosis is diagnosed when the bone mineral density (BMD) is greater than 2.5 standard deviations below peak bone mass and osteopenia is diagnosed when the BMD is 1-2.5 standard deviations below peak bone mass [1]. This review article will discuss the relationship between low BMD and atherosclerotic vascular disease.

Atherosclerotic vascular disease

Dual energy X-ray absorptiometry (DEXA) scans were used to measure BMD in a retrospective case comparison pilot study in 101 postmenopausal women, mean age 76 years, in a nursing home affiliated with New York Medical College [2]. The DEXA scans were obtained because the United States Preventive Services Task Force and the National Osteoporosis Foundation recommend measuring BMD at least once in all women older than 65 years [3, 4]. BMD was measured in the hips and spine in all 101 patients by DEXA scan obtained from a computerized radiology database. Of 101 patients, 51 (51%) had a low BMD [2]. The mean age and prevalence of smoking, hypertension, diabetes mellitus, and hypercholesterolemia were not significantly different between women with a low BMD and those with a normal BMD. However, atherosclerotic vascular disease defined as symptomatic coronary artery disease, cerebrovascular disease, or peripheral arterial disease was present in 31 of 51 women (61%) with osteoporosis or osteopenia versus 19 of 38 women (38%) with normal BMD (p< 0.025) [2]. Coronary artery disease and cerebrovascular disease were diagnosed as previously described [5-8]. A retrospective analysis was performed in 1000 postmenopausal women, mean age 68 years (range 51 to 97 years), seen consecutively at a general medicine clinic at the University of Iowa School of Medicine to investigate the prevalence of atherosclerotic vascular disease in women with osteoporosis, osteopenia, and no osteoporosis or osteopenia [9]. Women were diagnosed as having osteoporosis or osteopenia according to the criteria of the World Health Organization [1]. Of 1000 women, 154 (15%) had osteoporosis, 179 (18%) had osteopenia, and 667 (67%) had no osteoporosis or osteopenia [9]. The mean age and prevalence of race, current cigarette smoking, hypertension, diabetes mellitus, and hypercholesterolemia were not significantly different between women with osteoporosis, osteopenia, and no osteoporosis or osteopenia. Atherosclerotic vascular disease was defined as the presence of coronary artery disease, ischemic stroke, or peripheral arterial disease. Atherosclerotic vascular disease occurred in 92 of 154 women (60%) with osteoporosis, in 63 of 179 women (35%) with osteopenia, and in 148 of 667 women (22%) with no osteoporosis or osteopenia. P values were < 0.001 comparing osteoporosis with osteopenia, < 0.001 comparing osteoporosis with no osteoporosis or osteopenia, and < 0.001 comparing osteopenia with no osteoporosis or osteopenia [9]. In 31 936 Swedish twins followed up from age 50 years, the adjusted hazard ratio for hip fracture was significantly increased 4.40 times after a diagnosis of heart failure, 5.09 times after a diagnosis of stroke, 3.20 times after a diagnosis of peripheral arterial disease, and 2.32 times after a coronary event [10].

Coronary artery disease

In 5050 women and men aged 50 to 79 years, self-reported myocardial infarction was insignificantly increased by 22% in women with a low BMD and was significantly increased (p= 0.03) by 39% in men with a low BMD [11]. In 45 postmenopausal women who had DEXA scans and coronary artery calcium scores measured, the latter were 42 for women with a normal BMD, 182 for women with osteopenia, and 222 for women with osteoporosis, suggesting that women with a low BMD are at higher risk of coronary atherosclerosis [12]. Using the Framingham coronary heart disease risk prediction algorithm in 1804 women aged 50 to 74 years, women with a 10% to 19% coronary heart disease risk within 10 years were significantly 45% more likely to have a low BMD than women with a less than 10% chance of developing coronary heart disease within 10 years [13]. Women with a 20% or higher coronary heart disease risk within 10 years were significantly 73% more likely to have a low BMD than women with a less than 10% chance of developing coronary heart disease within 10 years. Similar increases in low BMD risk were not observed in men [13]. Marcovitz et al. showed in 209 patients (89% women and 11% men), mean age 67 years, that obstructive coronary artery disease with ≥ 50% narrowing of at least 1 major coronary artery was present in 122 of 157 patients (78%) with a low BMD and in 26 of 52 patients (50%) with a normal BMD (p< 0.001) [14]. In this study, multivessel coronary artery disease was present in 86 of 157 patients (55%) with a low BMD and in 13 of 52 patients (25%) with a normal BMD (p = 0.0002). The DEXA scans and coronary angiograms were performed within the same 12-month period. Multivariate step-down logistic regression analysis showed that significant independent predictors of obstructive coronary artery disease were osteoporosis (odds ratio [OR] = 5.58), hypertension (OR = 3.92), family history of premature coronary artery disease (OR = 2.99), and fasting glucose level greater than 110 mg/dl (OR = 3.28) [14]. Osteoporosis and osteopenia were also significantly associated with any degree of vessel narrowing [14]. Coronary angiography was performed because of chest pain in 198 patients (76% women and 24% men), mean age 66 years, who had DEXA scans of the spine and left hip because of suspected osteoporosis or osteopenia within 6 months of coronary angiography [15]. Osteoporosis was diagnosed when the T score was < –2.5 standard deviations below peak bone mass and osteopenia was diagnosed when the T score was –1.0 to –2.5 standard deviations below peak bone mass [16]. Normal BMD was diagnosed if the T score was > –1.0 standard deviations below peak bone mass [16]. Obstructive coronary artery disease was diagnosed if there was > 50% diameter narrowing of at least 1 major coronary artery. Of 198 patients, 53 (27%) had osteoporosis, 79 (40%) had osteopenia, and 66 (33%) had normal BMD. The prevalence of gender, mean age, prior myocardial infarction, current smoking, hypertension, diabetes mellitus, hypercholesterolemia, and body mass index ≥ 30 kg/m2 were not significantly different between patients with osteoporosis, osteopenia, and normal BMD. Obstructive coronary artery disease with > 50% narrowing of at least 1 major coronary artery was present in 40 of 53 patients (76%) with osteoporosis, in 54 of 79 patients (68%) with osteopenia, and in 31 of 66 patients (47%) with normal BMD (p< 0.005 comparing osteoporosis with normal BMD and p< 0. 01 comparing osteopenia with normal BMD) [15]. The prevalence of obstructive coronary artery disease was significantly higher in women with osteoporosis (74%) or osteopenia (66%) than in women with normal BMD (45%) [15]. The prevalence of obstructive coronary artery disease was 80% in men with osteoporosis, 75% in men with osteopenia, and 53% in men with normal BMD [15]. These differences were not significantly different because of the small number of men included in the study. These data confirmed the association of obstructive coronary artery disease with osteoporosis and osteopenia reported by Marcovitz et al. [14]. A retrospective analysis of 47 men, mean age 65 years, who had DEXA scans and coronary angiography showed that low BMD was an independent predictor of obstructive coronary artery disease with an odds ratio of 5.4 (95% CI, 1.66 to 17.49) [17]. The mechanism of this association remains to be investigated.

Osteopontin

Osteopontin is a noncollagenous bone matrix protein produced by osteocytes, osteoblasts, and osteoclasts that can interact with the cell surface receptor CD 44 [18, 19]. Osteopontin is associated with the presence and extent of coronary artery disease [20]. In 178 patients undergoing coronary angiography, mean age 65 years, plasma osteopontin levels were significantly associated with coronary artery disease, independent of other risk factors [20]. Coronary artery calcification was present in 86 of 178 patients (48%). Plasma osteopontin levels were higher in patients with coronary artery calcification than in patients without coronary artery calcification (p< 0.01) and correlated with the number of calcified segments (p < 0.001), but were not independently associated with coronary artery calcification [20]. Production of osteopontin by circulating endothelial progenitor cells at sites of tissue injury may modulate proliferation, migration, and accumulation of endothelial and vascular smooth muscle cells, promoting vascular repair but initiating vascular calcification [19, 21, 22]. The same proinflammatory factors involved in the pathogenesis of osteoporosis may lead to expression of an osteogenic phenotype by endothelial lineage cells, providing a potential mechanism for the association between osteoporosis and coronary artery disease [19]. Observational data support the association of osteopontin with atherosclerotic and valvular heart disease [23]. An increased osteoprotegerin level may be an indicator of a proinflammatory milieu that promotes atherosclerosis [24].

Exercise stress testing

Exercise capacity measured by exercise stress testing is a predictor of coronary mortality independent of traditional risk factors for coronary artery disease [25-27]. Showing an association between BMD and exercise capacity could help explain the association between BMD and coronary artery disease [28]. Therefore, From et al. studied a cohort of patients who had undergone both exercise echocardiography and DEXA scans to determine whether patients with low BMD had lower exercise capacities and were more likely to have exercise-induced ischemic changes during exercise echocardiography than patients with normal BMD [28]. Of 1142 patients, mean age 64 years, included in this study, 1001 (88%) were women and 141 (12%) were men [24]. Of the 1142 patients, 126 (11%) had osteoporosis, 517 (45%) had osteopenia, and 499 (44%) had normal BMD. Reasons for stopping the exercise echocardiographic stress test were fatigue in 761 patients (67%), dyspnea in 273 patients (24%), hypertension in 66 patients (6%), leg distress in 46 patients (4%), angina pectoris in 15 patients (1%), completion of protocol in 18 patients (2%), and reduction of blood pressure in 10 patients (1%). The treadmill exercise duration was 7.3 min in patients with a low BMD versus 8.1 min in patients with a normal BMD (p< 0.001) [28]. Myocardial ischemia developed during exercise echocardiography in 21% of patients with low BMD versus 14.7% of patients with normal BMD (p = 0.007). Patients with normal BMD had lower wall motion score indexes during exercise echocardiography than patients with low BMD (p < 0.001 by Wilcoxon rank sum test). For every 1-unit reduction in femoral neck T score, a 0.23 min significant reduction in treadmill exercise duration was found after values were adjusted for age and other patient characteristics. For every 1-unit reduction in femoral neck T score, there was a significant 22% increased risk of myocardial ischemia after values were adjusted for age and other patient characteristics. Overall after adjustments, patients with a low BMD who were referred for exercise echocardiographic stress testing, had a 43% significantly greater risk of myocardial ischemia, than did patients with normal BMD [28]. This study was the first study to demonstrate that low BMD is associated with exercise-induced myocardial ischemia and with reduced exercise capacity [28]. From et al. stated that the association between low BMD and reduced exercise capacity suggests that reduced physical activity may in part explain the relationship between low BMD and myocardial ischemia [28]. These findings support the studies that have linked increased mortality and higher bone turnover to reduced physical activity [29, 30]. From et al. suggested that reduced physical activity contributes to both low BMD and coronary artery disease through the development of atherosclerotic vascular disease [28]. Reduced exercise capacity and reduced physical activity are well established predictors of coronary artery disease and mortality [25-27]. These findings are strengthened by research findings demonstrating that various proteins known to regulate bone formation and bone resorption, including osteoprotegerin, matrix Gla protein, bone morphogenetic protein and osteopontin, are present in calcified atherosclerotic lesions [31]. DEXA scans of the spine and left hip were obtained prior to stress testing for myocardial ischemia in 629 women (82%) and 136 men (18%), mean age 63 years, with chest pain typical of ischemia and no prior history of coronary artery disease [32]. No patients with BMD measurements were excluded from this study. Of the 765 patients, 342 (45%) had an adenosine sestamibi or dipyridamole stress test, 336 (44%) had a treadmill sestamibi stress test, 80 (10%) had a treadmill stress test, and 7 (1%) had an exercise stress echocardiogram. A treadmill stress test was considered positive if ST-segment depression developed at least 1.0 mm below the resting level, with the ST segment extending horizontally for at least 80 msec after the J point or with downsloping of the ST-segment. In the presence of resting ST-segment depression, an increase of at least 2.0 mm below the resting level was required [33]. Stress tests were analyzed for the presence of myocardial ischemia without knowledge whether the patient had osteoporosis, osteopenia, or normal BMD. Osteoporosis was diagnosed if the T score was < –2.5 standard deviations below peak bone mass [16]. Osteopenia was diagnosed if the T score was –1.0 to –2.5 standard deviations below peak bone mass [16]. Normal BMD was diagnosed if the T score was > –1.0 standard deviations below peak bone mass [16]. Of the 765 patients, 254 (33%) had osteoporosis, 260 (34%) had osteopenia, and 251 (33%) had normal BMD [32]. The mean age and prevalence of gender, hypertension, hypercholesterolemia, diabetes mellitus, current smoking, body mass index ≥ 30 kg/m2, and estimated glomerular filtration rate < 60 ml/min/1.73 m2 were not significantly different between patients with osteoporosis, osteopenia, and normal BMD. Stress test-induced myocardial ischemia developed in 95 of 254 patients (37%) with osteoporosis, in 81 of 260 patients (31%) with osteopenia, and in 62 of 251 patients (25%) with normal BMD (p= 0.009) (p= 0.002 comparing osteoporosis with normal BMD; p= 0.007 comparing osteoporosis or osteopenia with normal BMD) [32]. The increased prevalence of myocardial ischemia in patients with low BMD was observed for both exercise and pharmacological stress testing. Stepwise logistic regression analysis to identify significant independent risk factors for stress test-induced myocardial ischemia were hypertension (OR = 1.7), diabetes mellitus (OR = 2.3), body mass index ≥ 30 kg/m2 (OR = 1.6), age (OR = 1.02 per year increase in age), and low BMD. Patients with osteoporosis or osteopenia had a 1.7 times higher chance of stress test-induced myocardial ischemia than those with normal BMD after controlling the confounding effects of hypertension, diabetes mellitus, body mass index, and age [32]. These data confirmed the association between low BMD and stress test-induced myocardial ischemia reported by From et al. [28]. Tanko et al. found in 2576 women, mean age 67 years, in the placebo group of the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized study that the risk of cardiovascular events significantly increased incrementally with the number and increasing severity of baseline vertebral fractures [34]. After adjustment for potential confounders, women with osteoporosis had a 3.9 times significantly increased risk for cardiovascular events compared with women with low bone mass [34]. These investigators recommended that treatment of postmenopausal osteoporosis should include consideration of measures to prevent cardiovascular events.

Aortic valve calcification

An association between low BMD and increased prevalence of aortic valve calcification [35] and of abdominal aortic calcifications [36] has been observed in older women with low BMD. Skolnick et al. also demonstrated in 55 patients with osteoporosis and aortic stenosis that treatment of osteoporosis was associated with a significant reduction in progression of aortic stenosis at 2.4-year follow-up [37]. These data warrant further investigation.

Mechanisms

As discussed, mechanisms for the association between low BMD and atherosclerotic vascular disease and valvular calcification include common risk factors including smoking, hypertension, physical inactivity, dyslipidemia, and menopause. Increased plasma osteopontin levels and proinflammatory factors as discussed also play a role. Osteoprotegerin-deficient mice develop early onset osteoporosis and calcification of the aorta and renal arteries [38]. An atherogenic high fat diet reduces bone formation in mice [39]. Use of statins has been associated with higher BMD [40] and decreased risk of fractures [41, 42]. Mice lacking the gene for matrix gla protein have vascular calcification, osteopenia, and fractures [43]. The ApoE 4 gene is also associated with decreased BMD and increased risk of fractures [44, 45]. In conclusion, on the basis of the available findings, patients with osteoporosis or osteopenia should be considered of high cardiovascular risk, especially when other major cardiovascular risk factors coexist. Exercise stress testing could be the diagnostic method of choice to rule out coronary artery disease in these patients. Patients with osteoporosis or osteopenia should also be treated with intensive risk factor modification in addition to treatment of the osteoporosis or osteopenia. Further studies are indicated to investigate the mechanisms by which low BMD is associated with coronary artery disease, stress test-induced myocardial ischemia, atherosclerotic vascular disease, and aortic valve calcification.
  40 in total

1.  Statin lipid-lowering drugs and bone mineral density.

Authors:  Daniel H Solomon; Joel S Finkelstein; Philip S Wang; Jerry Avorn
Journal:  Pharmacoepidemiol Drug Saf       Date:  2005-04       Impact factor: 2.890

2.  Aortic valve calcification: association with bone mineral density and cardiovascular risk factors.

Authors:  Yuksel Aksoy; Cengiz Yagmur; Gulacan Ozgun Tekin; Julide Yagmur; Ergun Topal; Ersoy Kekilli; Hasan Turhan; Feridun Kosar; Ertan Yetkin
Journal:  Coron Artery Dis       Date:  2005-09       Impact factor: 1.439

3.  Atherogenic high-fat diet reduces bone mineralization in mice.

Authors:  F Parhami; Y Tintut; W G Beamer; N Gharavi; W Goodman; L L Demer
Journal:  J Bone Miner Res       Date:  2001-01       Impact factor: 6.741

4.  Osteoporosis and coronary atherosclerosis in asymptomatic postmenopausal women.

Authors:  E I Barengolts; M Berman; S C Kukreja; T Kouznetsova; C Lin; E V Chomka
Journal:  Calcif Tissue Int       Date:  1998-03       Impact factor: 4.333

5.  Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study.

Authors:  Julie A Pasco; Mark A Kotowicz; Margaret J Henry; Kerrie M Sanders; Geoffrey C Nicholson
Journal:  Arch Intern Med       Date:  2002-03-11

6.  Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro.

Authors:  L Liaw; M Almeida; C E Hart; S M Schwartz; C M Giachelli
Journal:  Circ Res       Date:  1994-02       Impact factor: 17.367

7.  Receptor-ligand interaction between CD44 and osteopontin (Eta-1).

Authors:  G F Weber; S Ashkar; M J Glimcher; H Cantor
Journal:  Science       Date:  1996-01-26       Impact factor: 47.728

8.  Cardiovascular diseases and risk of hip fracture.

Authors:  Ulf Sennerby; Håkan Melhus; Rolf Gedeborg; Liisa Byberg; Hans Garmo; Anders Ahlbom; Nancy L Pedersen; Karl Michaëlsson
Journal:  JAMA       Date:  2009-10-21       Impact factor: 56.272

9.  Osteocalcin expression by circulating endothelial progenitor cells in patients with coronary atherosclerosis.

Authors:  Mario Gössl; Ulrike I Mödder; Elizabeth J Atkinson; Amir Lerman; Sundeep Khosla
Journal:  J Am Coll Cardiol       Date:  2008-10-14       Impact factor: 24.094

10.  Plasma osteopontin levels are associated with the presence and extent of coronary artery disease.

Authors:  Reiko Ohmori; Yukihiko Momiyama; Hiroaki Taniguchi; Rie Takahashi; Masatoshi Kusuhara; Haruo Nakamura; Fumitaka Ohsuzu
Journal:  Atherosclerosis       Date:  2003-10       Impact factor: 5.162

View more
  17 in total

1.  Bone mineral density in patients with obstructive sleep apnea syndrome.

Authors:  Sophia E Schiza; Izolde Bouloukaki; Charalampos Mermigkis
Journal:  Sleep Breath       Date:  2012-04-13       Impact factor: 2.816

2.  Vitamin D deficiency and osteoporosis in stroke survivors: an analysis of National Health and Nutritional Examination Survey (NHANES).

Authors:  Derya Uluduz; Malik M Adil; Basit Rahim; Waqas I Gilani; Haseeb Abdul Rahman; Sarwat I Gilani; Adnan I Qureshi
Journal:  J Vasc Interv Neurol       Date:  2014-05

3.  Osteoporosis as an independent risk factor for silent brain infarction and white matter changes in men and women: the PRESENT project.

Authors:  Y K Minn; S H Suk; S Y Do
Journal:  Osteoporos Int       Date:  2014-07-11       Impact factor: 4.507

4.  The impact of statin therapy on long-term cardiovascular outcomes in an outpatient cardiology practice.

Authors:  Hoang M Lai; Wilbert S Aronow; Anthony D Mercando; Phoenix Kalen; Harit D Desai; Kaushang Gandhi; Mala Sharma; Harshad Amin; Trung M Lai
Journal:  Med Sci Monit       Date:  2011-12

5.  Incidence of new cardiovascular events in patients with and without peripheral arterial disease seen in a vascular surgery clinic.

Authors:  Amit Chhabra; Wilbert S Aronow; Chul Ahn; Kurt Duncan; Jay D Patel; Alexander I Papolos; Babu Sateesh
Journal:  Med Sci Monit       Date:  2012-03

6.  Bone metabolism assessment, bone metabolism index designation and the determination of its normal values range in young healthy women.

Authors:  Wiesław Tryniszewski; Mariusz Gadzicki; Magdalena Górska-Chrząstek; Jacek Rysz; Zbigniew Maziarz
Journal:  Med Sci Monit       Date:  2011-10

7.  Behind the pathogenesis of osteoporosis and cardiovascular diseases.

Authors:  Pooneh Salari; Mohammad Abdollahi
Journal:  Arch Med Sci       Date:  2011-09-02       Impact factor: 3.318

8.  Peripheral arterial disease of the lower extremities.

Authors:  Wilbert S Aronow
Journal:  Arch Med Sci       Date:  2012-05-09       Impact factor: 3.318

9.  The impact of statin therapy on long-term cardiovascular outcomes in an outpatient cardiology practice.

Authors:  Hoang M Lai; Wilbert S Aronow; Anthony D Mercando; Phoenix Kalen; Harit V Desai; Kaushang Gandhi; Mala Sharma; Harshad Amin; Trung M Lai
Journal:  Arch Med Sci       Date:  2012-02-29       Impact factor: 3.318

10.  Risk factor reduction in progression of angiographic coronary artery disease.

Authors:  Hoang M Lai; Wilbert S Aronow; Anthony D Mercando; Phoenix Kalen; Harit V Desai; Kaushang Gandhi; Mala Sharma; Harshad Amin; Trung M Lai
Journal:  Arch Med Sci       Date:  2012-07-04       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.